Is Pfizer a good stock to buy in 2026?

<h2>Navigating the Balance of Risk and Resilience</h2> <p>Sure, there are real hurdles on the horizon—think steep revenue cliffs and the pinch of losing high-margin <strong>LOE</strong> products.</p> <p>Even so, stellar <strong>1Q26 fundamentals</strong> and whispers of a <strong>2026 guidance upgrade</strong> give it a surprisingly sturdy foundation to lean on.</p>